Health-related quality of life and cancer clinical trials
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The measurement of patient-reported outcomes, including health-related quality of life, is a new initiative which has emerged and grown over the past four decades. Following the development of reliable and valid self-report questionnaires, health-related quality of life has been assessed in tens of thousands of patients and a wide variety of cancers. This review is based on a selection of data published in the last decade and is intended primarily for healthcare professionals. The assessments in clinical trials have been particularly useful for elucidating the effects of various cancers and their treatments on patients’ lives and have provided additional information that enhances the usual clinical endpoints used for determining the benefits and toxicity of treatment. With growing experience the quality of the health-related quality of studies has improved and, in general, recent studies are more likely to be methodologically robust than those that were performed in earlier decades. Health-related quality of life has become a more accurate predictor of survival than some other clinical parameters, such as performance status. The overall outlook for the routine assessment of patient-reported outcomes in clinical trials is assured and, eventually, it is likely to become a standard part of clinical practice. However, there is still a need for a clear method for determining the clinical meaningfulness of changes in scores. The answer will probably come from the greater use of patient-reported outcomes and the consequent growth of experience that is necessary to make such judgements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000678 · Cited by 7,482 · cited 2×
“…et al. 2005]. http://tam.sagepub.com 61 Palliative care, symptom control and supportive care Patients with newly diagnosed metastatic NSCLC who were assigned to early palliative care had higher HRQOL scores at 12 weeks than did patients assigned to standard care (p¼ 0.03) [Temel et al. 2010].”
BackgroundInfluentialDocetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 2×
“Docetaxel plus mitoxantrone provided longer survival and improvement in pain and HRQOL compared with mitoxantrone and prednisone [Tannock et al. 2004a].”
BackgroundCella, D., Riley, W., Stone, A., Rothrock, N., Reeve, B., Yount, S., Amtmann, D., Bode, R., Buysse, D., Choi, S., et al. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.011 · Cited by 5,128
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700 · cited 2×
“5 standard deviation that has been suggested as being universally acceptable [Norman et al. 2003] although 0.”
BackgroundMethodInfluentialIntegrating response shift into health-related quality of life research: a theoretical model
Sprangers, M. A. G., & Schwartz, C. E. (1999) · Social Science & Medicine · doi:10.1016/s0277-9536(99)00045-3 · Cited by 2,228 · cited 1×
“Response shift is the name given to an adaptation response resulting from changes in an individual’s internal standards, values and/or conceptualization [Sprangers, 2010; Schwartz et al. 2006; Sprangers and Schwartz, 1999a, 1999b; Sprangers et al. 1999].”
BackgroundCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904 · cited 2×
“In patients with advanced, chemotherapyrefractory CRC, cetuximab improved overall and progression-free survival, particularly in patients with wild-type KRAS tumours [Jonker et al. 2007].”
BackgroundVelikova, G., Booth, L., Smith, A. B., Brown, P. M., Lynch, P., Brown, J. M., & Selby, P. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.078 · Cited by 1,382
Detmar, S. B., Muller, M. J., Schornagel, J. H., Wever, L. D. V., & Aaronson, N. K. (2002) · JAMA · doi:10.1001/jama.288.23.3027 · Cited by 1,011 · cited 2×
“Routine assessment in clinical practice Although PROM is becoming standard practice in clinical investigation and also has been shown to be of value in clinical practice [Velikova et al. 2010, 2004; Detmar et al. 2002], it still has not become a routine procedure.”
MethodResultCarlson, L. E., Speca, M., Patel, K. D., & Goodey, E. (2003) · Psychosomatic Medicine · doi:10.1097/01.psy.0000074003.35911.41 · Cited by 773 · cited 2×
“range from mindfulness-based stress-reduction programs [Foley et al. 2010; Ando et al. 2009; Lengacher et al. 2009; Witek-Janusek et al. 2008; Carlson et al. 2003], to yoga [Vadiraja et al.”
BackgroundLengacher, C. A., Johnson‐Mallard, V., Post‐White, J., Moscoso, M. S., Jacobsen, P. B., Klein, T. W., Widen, R. H., Fitzgerald, S. G., Shelton, M. M., Barta, M., et al. (2009) · Psycho-Oncology · doi:10.1002/pon.1529 · Cited by 518 · cited 2×
“range from mindfulness-based stress-reduction programs [Foley et al. 2010; Ando et al. 2009; Lengacher et al. 2009; Witek-Janusek et al. 2008; Carlson et al. 2003], to yoga [Vadiraja et al.”
BackgroundWitek-Janusek, L., Albuquerque, K., Chroniak, K. R., Chroniak, C., Durazo-Arvizu, R., & Mathews, H. L. (2008) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.01.012 · Cited by 506
Ganz, P. A., Kwan, L., Stanton, A. L., Krupnick, J. L., Rowland, J. H., Meyerowitz, B. E., Bower, J. E., & Belin, T. R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh060 · Cited by 505
Foley, E., Baillie, A., Huxter, M., Price, M., & Sinclair, E. (2010) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0017566 · Cited by 268 · cited 2×
“Such measures range from mindfulness-based stressreduction programs [Foley et al. 2010; Ando et al. 2009; Lengacher et al. 2009; WitekJanusek et al. 2008; Carlson et al. 2003], to yoga [Vadiraja et al.”
BackgroundVadiraja, H. S., Rao, M. R., Nagarathna, R., Nagendra, H. R., Rekha, M., Vanitha, N., Gopinath, K. S., Srinath, B. S., Vishweshwara, M. S., Madhavi, Y. S., et al. (2009) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2009.06.004 · Cited by 183 · cited 2×
“2003], to yoga [Vadiraja et al. 2009], to diet and exercise [Wolin et al.”
BackgroundShould Patient-Rated Performance Status Affect Treatment Decisions in Advanced Lung Cancer?
Dajczman, E., Kasymjanova, G., Kreisman, H., Swinton, N., Pepe, C., & Small, D. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318186a272 · Cited by 74
Cited by
Sherwood, A., Blumenthal, J. A., Koch, G. G., Hoffman, B. M., Watkins, L. L., Smith, P. J., O’Connor, C. M., Adams, K. F., Rogers, J. G., Sueta, C., et al. (2017) · Circulation: Heart Failure · doi:10.1161/circheartfailure.116.003410 · Cited by 55
Metadata
- Authors
- Osoba, D.
- Venue
- Therapeutic Advances in Medical Oncology
- Publisher
- SAGE Publications
- Published
- 2011-01-20
- Volume
- 3
- Issue
- 2
- Pages
- 57-71
- ISSN
- 1758-8340 (ISSN-L)
- 1758-8359
- OpenAlex
- W2139562398
- Cited by
- 231
- References
- 16
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.